ITB-Med LLC
ITB-MED is dedicated to developing innovative immunomodulatory therapies, particularly focusing on its proprietary monoclonal antibody TCD601 (siplizumab), for applications in transplantation and autoimmunity. The company aims to provide immunosuppression freedom to improve patient outcomes and quality of life, with ongoing clinical trials and a broad project portfolio.
Industries
Nr. of Employees
small (1-50)
Products
Antagonistic CD2-directed monoclonal antibody (clinical-stage immunomodulatory therapy)
A CD2-targeted monoclonal antibody therapeutic approach in clinical development intended to modulate immune responses for induction of transplantation tolerance and treatment of autoimmune conditions.
Antagonistic CD2-directed monoclonal antibody (clinical-stage immunomodulatory therapy)
A CD2-targeted monoclonal antibody therapeutic approach in clinical development intended to modulate immune responses for induction of transplantation tolerance and treatment of autoimmune conditions.
Services
Expanded access / compassionate-use program
Evaluation and provision of investigational product access to eligible patients outside clinical trials, upon physician request and subject to medical and regulatory criteria.
Global clinical trial execution
Sponsorship and operational execution of clinical trials across multiple jurisdictions to generate safety and efficacy data for regulatory submissions.
Expanded access / compassionate-use program
Evaluation and provision of investigational product access to eligible patients outside clinical trials, upon physician request and subject to medical and regulatory criteria.
Global clinical trial execution
Sponsorship and operational execution of clinical trials across multiple jurisdictions to generate safety and efficacy data for regulatory submissions.
Expertise Areas
- Transplantation tolerance therapies
- Autoimmunity therapeutics
- Clinical development and trial management
- CMC and biologics manufacturing strategy
Key Technologies
- Monoclonal antibody therapeutics
- CD2-directed immunotherapy
- Immunomodulation and tolerance induction
- Clinical trial platforms (IND through Phase 1/2)